composition-dependent in vivo antitumor activity of adriamycin-conjugated polymeric micelle against murine colon adenocarcinoma 26
暂无分享,去创建一个
Kazuya Okamoto | Teruo Okano | Kazunori Kataoka | Yasuhisa Sakurai | T. Okano | K. Kataoka | G. Kwon | Y. Sakurai | M. Yokoyama | Masayuki Yokoyama | Glenn S. Kwon | Hisao Ekimoto | Hiroko Mashiba | Takashi Seto | H. Ekimoto | K. Okamoto | T. Seto | H. Mashiba
[1] K. Kataoka,et al. Preparation of adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. A new type of polymeric anticancer agent , 1987 .
[2] J. Kopecek,et al. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. I. Evaluation of daunomycin and puromycin conjugates in vitro. , 1987, British Journal of Cancer.
[3] T. Okano,et al. Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. , 1990, Cancer research.
[4] M. Hashida,et al. Disposition characteristics of mitomycin C-dextran conjugate in normal and tumor-bearing muscles of rabbits. , 1987, Cancer research.
[5] A. Gabizon,et al. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[6] J. Koziol,et al. Preclinical trials with combinations and conjugates of T101 monoclonal antibody and doxorubicin. , 1986, Cancer research.
[7] F. Zunino,et al. Poly(carboxylic acid) polymers as carriers for anthracyclines , 1989 .
[8] J. Feijen,et al. OPTIMIZATION OF MACROMOLECULAR PRODRUGS OF THE ANTITUMOR ANTIBIOTIC ADRIAMYCIN , 1985 .
[9] M. Bally,et al. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. , 1989, Cancer research.
[10] K. Fujimori,et al. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. , 1989, Cancer research.
[11] T. Okano,et al. Molecular design for missile drug: Synthesis of adriamycin conjugated with immunoglobulin G using poly(ethylene glycol)-block-poly(aspartic acid) as intermediate carrier , 1989 .
[12] R. Paxton,et al. Mechanism of decreasing liver uptake of 111In-labeled anti-carcinoembryonic antigen monoclonal antibody by specific antibody pretreatment in tumor bearing mice. , 1990, Cancer research.
[13] B. Wolff,et al. Fate of Liposomes In Vivo: Control Leading to Targeting , 1984 .
[14] Yokoyama Masayuki,et al. Polymer micelles as novel drug carrier: Adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer , 1990 .
[15] Y. Takeda,et al. A novel covalent modification of antibodies at their amino groups with retention of antigen-binding activity. , 1987, Journal of immunological methods.
[16] T. Okano,et al. Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. , 1991, Cancer research.
[17] J. Murray,et al. Lack of comparability between binding of monoclonal antibodies to melanoma cells in vitro and localization in vivo. , 1989, Journal of the National Cancer Institute.
[18] K. Ulbrich,et al. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 3. Evaluation of adriamycin conjugates against mouse leukaemia L1210 in vivo , 1989 .
[19] T M Allen,et al. Large unilamellar liposomes with low uptake into the reticuloendothelial system , 1987, FEBS letters.
[20] H. Ishitsuka,et al. Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. , 1990, Cancer research.
[21] K. Isselbacher,et al. Doxorubicin conjugates of monoclonal antibodies to hepatoma-associated antigens. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[22] R. Reisfeld,et al. Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[23] T. Tsuruo,et al. 4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent. , 1982, Cancer research.
[24] S. Penco,et al. Chemical and biological characterization of 4'-iodo-4'-deoxydoxorubicin. , 1987, Cancer research.
[25] E. Zocchi,et al. Encapsulation of adriamycin in human erythrocytes. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[26] R. Paxton,et al. Effect of specific antibody pretreatment on liver uptake of 111In-labeled anticarcinoembryonic antigen monoclonal antibody in nude mice bearing human colon cancer xenografts. , 1989, Cancer research.
[27] R K Jain,et al. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. , 1990, Journal of the National Cancer Institute.
[28] A. Rolland,et al. Enhancement of adriamycin antitumor activity by its binding with an intracellular sustained-release form, polymethacrylate nanospheres, in U-937 cells. , 1988, Cancer research.
[29] T. Tsuruo,et al. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines. , 1989, Cancer research.
[30] T. Okano,et al. Preparation of micelle-forming polymer-drug conjugates. , 1992, Bioconjugate chemistry.
[31] F. Zunino,et al. Poly-L-aspartic acid as a carrier for doxorubicin: a comparative in vivo study of free and polymer-bound drug. , 1985, British Journal of Cancer.